Can-Fite BioPharma Ltd.

CANF • Biotechnology

$2.23

▼ -0.12 (-5.11%)

Precio actual

ResultadosÚltimo reporte: 31 dic 2025

PERFIL DÉBILDébilConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil histórico débil. La evidencia actual no sostiene una relación riesgo/retorno favorable.

Capitalización

$720.89M

Crecimiento

-23.2%

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Nivel de deuda manejable · 0.01Liquidez saludable · 3.46Tendencia de crecimiento negativaRentabilidad débil

Datos financieros hasta: 31 dic 2025, 12:00 a.m. UTCÚltima actualización de earnings: 26 mar 2026, 12:00 a.m. UTCÚltima actualización del perfil: 2 sept 2026, 12:17 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$2.23

Change-5.11%

Shares Out323.27M

Market Cap$720.89M

Enterprise Value$712.35M

52W Range2.56 - 13.40

Beta0.02

P/E-73.35

P/S1,779.97

P/B128.91

P/FCF-80.54

EV/Sales1,758.89

Price$2.23

Change-5.11%

Shares Out323.27M

Market Cap$720.89M

Enterprise Value$712.35M

52W Range2.56 - 13.40

Beta0.02

P/E-73.35

P/S1,779.97

P/B128.91

P/FCF-80.54

EV/Sales1,758.89

EV/EBITDA-71.77

EV/FCF-79.58

Earnings Yield-1.36%

FCF Yield-1.24%

Dividend Yield0.00%

Gross Margin94.07%

Oper. Margin-24.57%

Profit Margin-24.27%

Debt/Eq0.01

Current Ratio3.46

Quick Ratio3.46

Revenue 5Y-23.15%

Target$8.00

Target Upside258.74%

Target Median$8.00

Target Range8.00 - 8.00

Volume15.32K

Avg Volume1.32M

EPS Surprise21.03

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

76/100

Potencial de crecimiento

Ingresos y expansión

20/100

Atractivo del precio

Barata o cara hoy

75/100

Por qué este puntaje▼

Nivel de deuda manejable · 0.01Liquidez saludable · 3.46Tendencia de crecimiento negativaRentabilidad débil

Analyst view

Analyst sentiment and price target

CANF

Analyst sentiment

Based on 4 analyst votes · 2026-09-05

88/100

Bullish

Hold

Bearish

Precio objetivo

2026-09-02

Bajo

$8.00

Promedio

$8.00

Mediana

$8.00

Alto

$8.00

Resumen de la compañía

IPO: 11/6/2012

Industria: Biotechnology

P/B i: 128.91

Deuda / Patrimonio i: 0.01

Margen operativo: -2456.80%

Margen neto: -2426.67%

ROE i: -

ROIC: -

Salud financiera

Puntaje15 / 20

Deuda / Patrimonio: 0.01

Ratio corriente: 3.46

Ratio rápido: 3.46

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

Fishman Pnina

Transacción: 06/04/2026

COMPRA

Cambio

+24,000

Precio

$2.04

Presentación

06/08/2026

Tipo

COMPRA

Farbstein Motti

Transacción: 06/04/2026

COMPRA

Cambio

+24,000

Precio

$2.04

Presentación

06/08/2026

Tipo

COMPRA

Tamir Ilan

Transacción: 04/25/2026

OTRO

Cambio

+16,000

Precio

$2.25

Presentación

04/23/2026

Tipo

OTRO

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Fishman Pnina	COMPRA	+24,000	$2.04	06/04/2026	06/08/2026
Farbstein Motti	COMPRA	+24,000	$2.04	06/04/2026	06/08/2026
Tamir Ilan	OTRO	+16,000	$2.25	04/25/2026	04/23/2026
Regev Guy	OTRO	+16,000	$2.18	04/25/2026	04/06/2026
Regev Guy	OTRO	0	Not reported	03/18/2026	04/06/2026
Regev Guy	OTRO	+2,166	$26.56	08/07/2024	04/06/2026
Regev Guy	OTRO	+2,166	$25.21	08/01/2023	04/06/2026
Regev Guy	OTRO	+200	$241.47	06/15/2020	04/06/2026
Regev Guy	OTRO	+16	$2826.14	02/08/2017	04/06/2026
Bornstein Yoseph	OTRO	+16,000	$2.18	04/25/2026	03/18/2026
Bornstein Yoseph	OTRO	+2,166	$26.56	08/07/2024	03/18/2026
Bornstein Yoseph	OTRO	+2,166	$25.21	08/01/2023	03/18/2026
Bornstein Yoseph	OTRO	+200	$241.47	06/22/2021	03/18/2026

Sobre la compañía

Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd., an Israeli clinical-stage biopharmaceutical company, specializes in the creation of small molecule therapeutic products. These treatments target a range of conditions including various cancers, inflammatory liver disorders, and erectile dysfunction. Its primary drug candidate, Piclidenoson, has successfully advanced through Phase III clinical trials for psoriasis and completed Phase II trials for COVID-19. Another promising asset, Namodenoson, is currently undergoing Phase III clinical evaluation for hepatocellular carcinoma (a form of liver cancer) and is in a Phase IIb study for non-alcoholic steatohepatitis (NASH). Furthermore, CF602 is in preclinical development, aimed at addressing erectile dysfunction. Beyond its drug pipeline, Can-Fite also commercializes a predictive biomarker blood test kit for A3AR. Strategic partnerships are also key to its operations; a licensing and collaboration agreement with CMS Medical covers the development, manufacturing, and commercialization of both Piclidenoson and Namodenoson. Additionally, the company collaborates with Univo Pharmaceuticals to identify and co-develop cannabis-derived formulations intended for various therapeutic applications, including cancer, inflammatory, autoimmune, and metabolic conditions. Originally incorporated in 1994 as Can-Fite Technologies Ltd., the company adopted its current name, Can-Fite BioPharma Ltd., in January 2001 and is headquartered in Petah Tikva, Israel.

Fuente - Link

Competidores

BDRX CLDI CMND CNSP GRI JAGX KZIA OGEN SILO SNGX

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Can-Fite BioPharma Evaluates Earlier Interim Analysis for Key Liver Cancer Study

Can-Fite BioPharma Ltd. (NYSE:CANF) reported extended survival trends in a key late-stage cancer trial alongside a $4 million warrant exercise agreement to fund ongoing clinical operations.

Benzinga

Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds

RAMAT GAN, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) (“Can-Fite” or the “Company”), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,591,738 American Depositary Shares (ADSs), having an exercise price of $5.00 per ADS, issued by Can-Fite in March 2026, at a reduced exercise price of $2.50 per ADS. The ADSs representing ordinary shares issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form F-3 (File No. 333-294760). The closing of the offering is expected to occur on or about September 3, 2026, subject to satisfaction of customary closing conditions.

GlobeNewsWire

Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study

Company plans to advance the interim analysis of its Phase III Namodenoson study in advanced hepatocellular carcinoma Ramat Gan, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd.

GlobeNewsWire

Can-Fite: Namodenoson Enhances the Anti-Cancer Effect of Chemotherapy in Pancreatic Cancer

The New Mechanistic Findings Support Can-Fite's Ongoing Phase IIb Study Design Following Positive Phase IIa Results Ramat Gan, Israel, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced new preclinical findings demonstrating that namodenoson enhances the anti-cancer effect of gemcitabine chemotherapy in pancreatic cancer.

GlobeNewsWire

Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates

Namodenoson Holds FDA Fast Track and U.S. and European Orphan Drug Designations; Piclidenoson and Namodenoson Are Advancing in Phase III Programs Ramat Gan, Israel, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today provided an update on the regulatory status of its two lead drug candidates, Piclidenoson and Namodenoson.

GlobeNewsWire

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-03-26	-26.9973	-5.97	21.0273
2025-04-14	-0.24	-0.21437	0.02563
2024-12-26	-0.27	-0.43	-0.16
2024-09-26	-0.36	-0.4	-0.04
2024-06-27	-0.4	-0.65	-0.25
2024-03-28	-5.4	-6.2	-0.8
2023-11-30	-8.6	-8.6	0
2023-08-31	-10.8	-8	2.8
2023-06-01	-1.52	-13	-11.48
2023-03-30	-11.4	-22.2	-10.8
2022-11-25	-20	-18	2
2022-08-25	-18	-16	2